CTOs on the Move

Lumen Bioscience

www.lumen.bio

 
Lumen Bioscience develops oral antibody therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lumen.bio
  • 1441 North 34th Street Suite 300
    Seattle, WA USA 98103
  • Phone: 206.899.1904

Executives

Name Title Contact Details

Funding

Lumen Bioscience raised $15.1M on 09/01/2020

Similar Companies

Tri State Surgical Supply

Tri State Surgical Supply is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apthera

Apthera, Inc. is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tscan

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Microbion

Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.

OWKIN

OWKIN builds mathematical models and algorithms that can interpret omics, visual data, biostatistics and patient profiles like never before. With OWKIN, patients directly benefit with more effective treatments.